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context, dosage regimens can be optimised through integration of PK-PD targets, derived from 80 both PK data and exposure-response data, with Monte Carlo simulation to predict the probability
81
of attaining a specific PD target at various dosage regimens.
15,22

82
The aim of this study was to determine the PK profile of intravenous meropenem given at an 
119
Pharmacokinetic analysis
120
A population PK modelling approach was applied to the data using NONMEM Version 7.2. 
RESULTS
184
Patient Demographics
185
Twelve patients (7 male) were recruited to the study with a mean age at the time of the first Table 1 .
236
The mean CL was 18.4 L/h and ranged from 5.3 to 36.0 L/h; mean estimates of distribution and 237 elimination half-lives were 0.4 h (range 0.3 to 0.6 h) and 2.9 h (range 1.3 to 9.7 h), respectively.
238
AUC 0-24 ranged from 83 to 563 mg·h/L (mean 226 mg·h/L).
239
The final population model parameters and non-parametric bootstrap estimates are presented in 240 Table 2 . From 1,000 replicates analysed during the bootstrap analysis, 11% failed to minimize . This is in line with another clinical study of beta-325 lactams which showed a significantly greater outcome when T >MIC was at least 80%. 40 In the 326 present study, a regimen of 1 g over 5 minutes every 8 h would be sufficient to achieve 80% 
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